76541-76-9

Upstream product

• 1660-94-2 Tetraethyl methylenediphosphonate 
• 637-59-2 1-Bromo-3-phenylpropane 
• 3277-89-2 phenethylmagnesium bromide 
• 37465-31-9 1,1-bis(diethylphosphono)ethylene 
• 34420-17-2 (2-phenylethyl)boronic acid 

Downstream Products

• 76541-81-6 tetramethyl (4-phenylbutylidene)bis(phosphonate) 
• 108816-78-0 [1-Chloro-1-(diethoxy-phosphoryl)-4-phenyl-butyl]-phosphonic acid diethyl ester 
• 76541-78-1 4-phenylbutylidene-1,1-bisphosphonic acid 

Relevant academic research and scientific papers

Copper-mediated 1,4-conjugate addition of boronic acids and indoles to vinylidenebisphosphonate leading to gem-bisphosphonates as potential antiresorption bone drugs

A wide range of gem-bisphosphonate tetraethyl esters as precursors for bisphosphonic acids, which are potent inhibitors of bone resorption, bearing alkyl, aryl, and indole substituents in the β position were prepared through the CuII-catalyzed 1,4-conjugate addition of boronic acids and indoles to vinylidenebisphosphonate tetraethyl ester.

Anti-inflammatory/antiarthritic ketonic bisphosphonic acid esters

Bisphosphonate ester 2 is an inhibitor of inflammation, but is devoid of antiarthritic effects. SAR studies on a series of related bisphosphonate esters resulted in compounds 6e, 6i, 6j, and 6m, which exhibited excellent inhibition of an arthritis model, in addition to potent anti-inflammatory effects.

gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity

New diphosphonate compounds and related derivatives were synthesized and investigated for their activity in specifically inducing plasma high density lipoproteins (HDL) and high density lipoprotein cholesterol (HDL-C) in normal rats. The screening of nume

Anti-atherosclerotic pharmaceutical compositions containing diphosphonate compounds

The present invention relates to a pharmaceutical composition for increasing the relative quantity of circulating high density lipoproteins favorable augmentating the alpha/beta lipoprotein cholesterol ratios and clearing cholesterol and lipids from certain tissues and inducing hypotensive activity comprising administering to a human an effective amount of a compound of the formula: STR1 where X is H, OH, or STR2 R and R' identical or different are H, CH3 or C2 H5 ; m is zero or 1; and A is selected from the group comprising (CH3)3 C--, Y--C6 H4 --, Y--C6 H4 --O--C(CH3)2 --, Y--C6 H4 --C(CH3)2 --, Y--C6 H4 --C(O)--C6 H4 --, Y--C6 H4 --(CH2)n -- and Y--C6 H4 --O--(CH2)n --, where n is an integer from 1 to 6 and Y is H, CH3, OCH3, a halogen, and a pharmaceutically acceptable excipient.